

## FUTURE PLANS AND USE OF [REDACTED]

### FUTURE PLANS

See “Business — Strategies” in this document for a detailed description of our future plans.

### USE OF [REDACTED]

Assuming an [REDACTED] of HK\$[REDACTED] per Share (being the mid-point of the [REDACTED] Range of between HK\$[REDACTED] and HK\$[REDACTED] per Share), we estimate that we will receive net [REDACTED] of approximately HK\$[REDACTED] from the [REDACTED] after deducting the [REDACTED] commissions and other estimated expenses paid and payable by us in connection with the [REDACTED] and assuming that the [REDACTED] is not exercised.

As China’s overall health and wellness market is expected to grow in the future, the demand for physician platform services, digital healthcare marketing services and RWS services are also expected to grow. See “Industry Overview” for more details. As such, we believe the demand for our business service offerings will grow in the future. In line with our strategies, we intend to use our [REDACTED] from the [REDACTED] for the purposes and in the amounts set forth below:

Major Categories	Sub-Categories	Specific Plans	% of Total [REDACTED]	Expected Timeframe
Approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED], is expected to be used for business expansion.	Approximately [REDACTED]%, or approximately HK\$[REDACTED], for developing and upgrading our content and service offerings of physician platform solutions and expanding our user base by attracting more registered physician users to make our <i>MedSci</i> platform the platform of choice for pharmaceutical and medical device companies in launching marketing campaigns	Recruiting and retaining 25 full-time medical experts and editors with extensive professional experience to enhance our academic medical knowledge and clinical study assistance capabilities with a salary range of RMB20,000 to RMB40,000 per month	[REDACTED]%	before December, 2025
		Increasing investment in content contributors to incentivize them to share their professional opinions and copyright owners to obtain licensed guidelines, papers and medical tools to diversify the knowledge library of our <i>MedSci</i> platform, creating more products that address the needs of our customers	[REDACTED]%	before December, 2024
		Attracting more registered physician users and driving up subscriptions by offering more premium contents on our <i>MedSci</i> platform	[REDACTED]%	before December, 2024

THIS DOCUMENT IS IN DRAFT FORM, INCOMPLETE AND SUBJECT TO CHANGE AND THAT THE INFORMATION MUST BE READ IN CONJUNCTION WITH THE SECTION HEADED “WARNING” ON THE COVER OF THIS DOCUMENT.

**FUTURE PLANS AND USE OF [REDACTED]**

Major Categories	Sub-Categories	Specific Plans	% of Total [REDACTED]	Expected Timeframe
		Extending the service portfolio to address physicians’ career development needs, such as personal intellectual property shaping that assists physicians and hospitals in opening up accounts on our platform to generate user-generated contents and various other academic medical contents and recruiting	[REDACTED]%	before December, 2024
	Approximately [REDACTED]%, or approximately HK\$[REDACTED], for expanding our RWS solutions and precision omni-channel marketing solutions through retaining existing and attracting new pharmaceutical and medical device companies	Recruiting and retaining a total of 25 full-time content creation talents to support medical content creation services, pharmacoeconomics specialists to enhance value delivered to pharmaceutical and medical device companies, industry veterans with medical background, clinical study operation and management experience to enhance our daily operations with a salary range of RMB15,000 to RMB35,000 per month	[REDACTED]%	before December, 2025
		Improving our training programs to equip our employees with the latest medical, industry and regulatory knowledge	[REDACTED]%	before December, 2024
		Expanding customer network of pharmaceutical and medical device companies through continuous sales and marketing efforts	[REDACTED]%	before December, 2024
Approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED], is expected to be used for further technology development.	Approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED], for expert recruitment and collaboration	Recruiting and retaining 10 well-known scientists, researchers and engineers full-time in the fields of AI, big data and VR with a salary range of RMB40,000 to RMB80,000 per month as well as 5 seasoned specialists with a minimum of two-years experience in the field of data analytics, natural language processing, deep learning and medical study full-time with a salary range of RMB30,000 to RMB80,000 per month	[REDACTED]%	before December, 2025

THIS DOCUMENT IS IN DRAFT FORM, INCOMPLETE AND SUBJECT TO CHANGE AND THAT THE INFORMATION MUST BE READ IN CONJUNCTION WITH THE SECTION HEADED “WARNING” ON THE COVER OF THIS DOCUMENT.

**FUTURE PLANS AND USE OF [REDACTED]**

Major Categories	Sub-Categories	Specific Plans	% of Total [REDACTED]	Expected Timeframe
		Exploring collaboration opportunities with universities renowned in the field of AI and big data to jointly develop digital therapy and diagnosis products	[REDACTED]%	after January 2023 and before December, 2024
	Approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED], for enhancing our technological capabilities to promote our existing solutions offerings	Upgrading our RWS solutions through improving current research assistance modules on data management, project management, smart data collection and statistical analysis and through integrating AI, block chain and wearable technology and other latest technology into our service offering	[REDACTED]%	before December, 2024
		Upgrading our precision omni-channel marketing solutions by enriching the service offerings and introducing new marketing solutions such as, among others, an enhanced precision detailing platform, a smart user profiling system and other new marketing models	[REDACTED]%	before December, 2024
	Approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED], for product innovation and development	Digital therapy programs covering more diseases	[REDACTED]%	before December, 2025
		VR diagnosis products with more clinical cases and better user interface	[REDACTED]%	before December, 2025
		Patient management tools	[REDACTED]%	before December, 2025
		Other digital tools that can empower hospitals to build their online research and development management system	[REDACTED]%	before December, 2025

THIS DOCUMENT IS IN DRAFT FORM, INCOMPLETE AND SUBJECT TO CHANGE AND THAT THE INFORMATION MUST BE READ IN CONJUNCTION WITH THE SECTION HEADED “WARNING” ON THE COVER OF THIS DOCUMENT.

**FUTURE PLANS AND USE OF [REDACTED]**

Major Categories	Sub-Categories	Specific Plans	% of Total [REDACTED]	Expected Timeframe
	Approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED], for enhancing our AI infrastructure	Purchasing a professional security system such as firewalls or other anti-hacking systems to safeguard our data and AI infrastructure	[REDACTED]%	before December, 2024
		Increasing spending on cloud-based computing by renting servers with data storage, emergency backup, big data and cloud-computing capabilities to support our platform and AI infrastructure and to build a better cloud system with useful clinical study assistance tools	[REDACTED]%	before December, 2024
		Recruiting and retaining 5 full-time research and development personnel with experience in data storage, server operation and maintenance with a salary range of RMB15,000 to RMB80,000 per month	[REDACTED]%	before December, 2025

THIS DOCUMENT IS IN DRAFT FORM, INCOMPLETE AND SUBJECT TO CHANGE AND THAT THE INFORMATION MUST BE READ IN CONJUNCTION WITH THE SECTION HEADED “WARNING” ON THE COVER OF THIS DOCUMENT.

**FUTURE PLANS AND USE OF [REDACTED]**

<u>Major Categories</u>	<u>Sub-Categories</u>	<u>Specific Plans</u>	<u>% of Total [REDACTED]</u>	<u>Expected Timeframe</u>
<p>Approximately [REDACTED]% of the net [REDACTED], or approximately HKS[REDACTED], is expected to be used for our potential investments and acquisitions or strategic alliances with companies that can generate synergies with our businesses. According to Frost &amp; Sullivan, there are approximately 50 companies that fit our criteria in China. As of the Latest Practicable Date, we have not identified any target for potential acquisition.</p>	<p>Planning to explore opportunities to invest in, or to acquire the equity interests of a) companies that operate platform solutions for medical professionals. We primarily focus on platform providers that cover at least 40% of the total medical professionals in any respective field, have a sufficient grassroots physician user base, or rank top three in their fields of operation, b) companies that can generate synergies with our RWS solutions that have a broad customer base and technology capabilities, c) companies that can generate synergies with our precision omni-channel marketing solutions with a relatively mature business operation team and products and d) companies that have a stable customer base and generate revenue in the most recent fiscal year with leading technology in the field of AI and diagnosis technology</p>		[REDACTED]%	after January 2023 and before December, 2025
	<p>Seek strategic cooperation opportunities with CROs focusing on serving medical products before the commercialization stage to generate synergies and with insurance companies in the field of commercial insurance and pharmacy catalog design and research</p>		[REDACTED]%	after January 2023 and before December, 2025
<p>Approximately [REDACTED]% of the net [REDACTED], or approximately HKS[REDACTED], is expected to be used for working capital and general corporate purposes</p>			[REDACTED]%	before December, 2024

---

## FUTURE PLANS AND USE OF [REDACTED]

---

In the event that the [REDACTED] is set at the Maximum [REDACTED] or the Minimum [REDACTED] of the indicative [REDACTED] range, the net [REDACTED] of the [REDACTED] will increase or decrease by approximately HK\$[REDACTED], respectively. If we make an Upward or Downward [REDACTED] Adjustment to set the final [REDACTED] to be above or below the mid-point of the [REDACTED] Range, we will increase or decrease the allocation of the net [REDACTED] to the above purposes on a pro rata basis.

The additional net [REDACTED] that we would receive if the [REDACTED] were exercised in full would be (i) HK\$[REDACTED] (assuming an [REDACTED] of HK\$[REDACTED] per Share, being the Maximum [REDACTED]), (ii) HK\$[REDACTED] (assuming an [REDACTED] of HK\$[REDACTED] per Share, being the mid-point of the [REDACTED] Range) and (iii) HK\$[REDACTED] (assuming an [REDACTED] of HK\$[REDACTED] per Share, being the Minimum [REDACTED]).

To the extent that the net [REDACTED] from the [REDACTED] (including the net [REDACTED] from the exercise of the [REDACTED]) are either more or less than expected, we may adjust our allocation of the net [REDACTED] for the above purposes on a pro rata basis.

To the extent that the net [REDACTED] of the [REDACTED] are not immediately required for the above purposes, or if we are unable to put into effect any part of our plan as intended, we will hold such funds in short-term deposits with licensed banks and/or authorized financial institutions so long as it is deemed to be in the best interests of the Company. In such event, we will comply with the appropriate disclosure requirements under the Listing Rules.